The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Denmark’s status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant’s astronomical ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

With semaglutide patents set to expire in 2026, Indian pharma giants are ramping up peptide production and device tie-ups to ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Key Takeaways Several key companies are slated to report earnings this week, including Palantir, AMD, McDonald’s, Pfizer, ...

Hims & Hers Health ($HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS ...